Lucid Diagnostics Inc LUCD:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 08/12/22 EDT
3.39quote price arrow up+0.04 (+1.19%)
Volume
184,240
52 week range
1.69 - 13.52
Loading...
  • Open3.36
  • Day High3.50
  • Day Low3.29
  • Prev Close3.35
  • 52 Week High13.52
  • 52 Week High Date10/14/21
  • 52 Week Low1.69
  • 52 Week Low Date06/16/22

Key Stats

  • Market Cap129.70M
  • Shares Out38.26M
  • 10 Day Average Volume0.15M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-36.87

KEY STATS

  • Open3.36
  • Day High3.50
  • Day Low3.29
  • Prev Close3.35
  • 52 Week High13.52
  • 52 Week High Date10/14/21
  • 52 Week Low1.69
  • 52 Week Low Date06/16/22
  • Market Cap129.70M
  • Shares Out38.26M
  • 10 Day Average Volume0.15M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-36.87

RATIOS/PROFITABILITY

  • EPS (TTM)-0.80
  • P/E (TTM)-4.22
  • Fwd P/E (NTM)-2.45
  • EBITDA (TTM)-27.415M
  • ROE (TTM)-
  • Revenue (TTM)500,000.00
  • Gross Margin (TTM)-17.00%
  • Net Margin (TTM)-5,615.60%
  • Debt To Equity (MRQ)3.81%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Lucid Diagnostics Inc

There is no recent news for this security.

Content From Our Affiliates

Profile

MORE
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). Its products include EsoCheck and EsoGuard. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in an...
Address
One Grand Central Place
Suite 4600, Suite 4600
New York, NY
10165
United States